CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy

被引：47
|
作者：
Murad, Yanal M.
Clay, Timothy M.
Lyerly, H. Kim
Morse, Michael A.
机构：
[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Program Mol Therapeut, Duke Comprehens Canc Ctr,Dept Pathol & Immunol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Program Mol Therapeut, Comprehens Canc Ctr,Dept Med, Durham, NC 27710 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
adjuvant; CPG-7909; PF-3512676; ProMune; TLR9;
D O I：
10.1517/14712598.7.8.1257
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
引用
收藏
页码：1257 / 1266
页数：10
相关论文
共 50 条
  • [1] Anti-tumor applications of activating toll-like receptor 9 with PF-3512676 (formerly CPG 7909)
    Krieg, Arthur M.
    EJC SUPPLEMENTS, 2006, 4 (06): : 15 - 15
  • [2] PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC)
    Readett, David R.
    Denis, Louis J.
    Krieg, Arthur M.
    Benner, Rebecca J.
    Hanson, Donald C.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S461 - S461
  • [3] Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Kim, Youn H.
    Girardi, Michael
    Duvic, Madeleine
    Kuzel, Timothy
    Link, Brian K.
    Brown, Lauren Pinter
    Rook, Alain H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (06) : 975 - 983
  • [4] Early development of the Toll-like receptor 9 agonist PF-3512676, for the treatment of patients with advanced cancers
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Krieg, Arthur M.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (05) : 587 - 603
  • [5] Toll-like-receptor 9 (TLR-9) agonist PF-3512676 (CPG 7909) in combination with chemotherapy in the treatment of non-small cell lung cancer (NSCLC)
    Gauler, T.
    Schuett, P.
    Eberhardt, W.
    ANNALS OF ONCOLOGY, 2007, 18 : 24 - 25
  • [6] Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer
    Belani, Chandra P.
    Nemunaitis, John J.
    Chachoua, Abraham
    Eisenberg, Peter D.
    Raez, Luiz E.
    Cuevas, J. Daniel
    Mather, Cecile B.
    Benner, Rebecca J.
    Meech, Sandra J.
    CANCER BIOLOGY & THERAPY, 2013, 14 (07) : 557 - 563
  • [7] RANDOMIZED PHASE II TRIAL OF ERLOTINIB WITH OR WITHOUT PF-3512676 (CPG 7909, A TOLL-LIKE RECEPTOR 9 [TLR9] AGONIST) IN PATIENTS WITH ADVANCED RECURRENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Belani, Chandra P.
    Nemunaitis, John J.
    Chachoua, Abraham
    Eisenberg, Peter D.
    Raez, Luis E.
    Cuevas, Juan D.
    Mather, Cecile B.
    Benner, Rebecca J.
    Meech, Sandra J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1218 - S1219
  • [8] Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-hodgkin's lymphoma
    Leonard, John R.
    Link, Brian K.
    Emmanouilides, Christos
    Gregory, Stephanie A.
    Weisdorf, Daniel
    Andrey, Jeffrey
    Hainsworth, John
    Sparano, Joseph A.
    Tsai, Donald E.
    Horning, Sandra
    Krieg, Arthur M.
    Weiner, George J.
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6168 - 6174
  • [9] Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    Hirsh, Vera
    Paz-Ares, Luis
    Boyer, Michael
    Rosell, Rafael
    Middleton, Gary
    Eberhardt, Wilfried E. E.
    Szczesna, Aleksandra
    Reiterer, Pavel
    Saleh, Mansoor
    Arrieta, Oscar
    Bajetta, Emilio
    Webb, Roy T.
    Raats, Johannes
    Benner, Rebecca J.
    Fowst, Camilla
    Meech, Sandra J.
    Readett, David
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2667 - 2674
  • [10] The TLR9 agonist PF-3512676 (Formerly CPG 7909) induces T cell-mediated tumor regression synergistically with paclitaxel or treg depletion in a metastatic murine cancer model
    Weeratna, Risini D.
    Vicari, Alain P.
    Bourne, Liana
    Davis, Heather L.
    Krieg, Arthur
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 678 - 679
12345